
Sail Biomedicines is a biopharmaceutical company operating at the frontier of programmable medicines. They leverage a proprietary bioplatform that harnesses evolution and AI to generate life-changing medicines. Their core technology includes Endless RNA™ (eRNA), a circular RNA format designed for prolonged protein expression, and programmable nanoparticles utilizing a broad range of natural chemistries for enhanced deployment and targeted delivery. Sail integrates these components with proprietary generative AI to design RNA medicines for a range of diseases including autoimmune, metabolic, infectious, and rare diseases. The company was formed in October 2023, combining over eight years of data and platform-building experience from the Flagship Pioneering ecosystem. They aim to achieve unprecedented performance in RNA medicine development.

Sail Biomedicines is a biopharmaceutical company operating at the frontier of programmable medicines. They leverage a proprietary bioplatform that harnesses evolution and AI to generate life-changing medicines. Their core technology includes Endless RNA™ (eRNA), a circular RNA format designed for prolonged protein expression, and programmable nanoparticles utilizing a broad range of natural chemistries for enhanced deployment and targeted delivery. Sail integrates these components with proprietary generative AI to design RNA medicines for a range of diseases including autoimmune, metabolic, infectious, and rare diseases. The company was formed in October 2023, combining over eight years of data and platform-building experience from the Flagship Pioneering ecosystem. They aim to achieve unprecedented performance in RNA medicine development.
Founded: October 2023
Headquarters: Somerville / Cambridge, Massachusetts, United States
Technology focus: Circular RNA (Endless RNA™) and programmable nanoparticle delivery
Notable funder: Bill & Melinda Gates Foundation (grant)
| Company |
|---|
Therapeutics for autoimmune, metabolic, infectious, and rare diseases
2023
Biotechnology Research
Reported as a single grant funding round; amount and date redacted in sources.
“Bill & Melinda Gates Foundation”
About Sail: Sail Biomedicines is pioneering the integrative design and deployment of fully programmable medicines to transform patient care. Sail’s platform combines first-in-class programmable circular RNA technology (Endless RNA™ or eRNA), and an industry-leading platform of programmable nanoparticles, utilizing natural components, to unlock comprehensive programming of medicines for the first time. By leveraging cutting-edge eRNA and nanoparticle deployment technology, Sail is building a wealth of data, enabling unparalleled use of generative AI techniques to identify and design fully programmable medicines that are potent, targeted, versatile, and tunable. Sail was founded by Flagship Pioneering.
The Role: SAIL Biomedicines is seeking a Director/Senior Director of DMPK & Clinical Pharmacology to lead our efforts in transitioning drug candidates into clinical development. This role will collaborate cross-functionally to drive program goals and shape strategies for preclinical DMPK & clinical pharmacology from preclinical through clinical stages. We’re looking for a strategic and visionary thinker with a hands-on approach, strong communication skills, and deep expertise in DMPK & Clinical Pharmacology.
Responsibilities:
Required Qualifications:
Preferred Qualifications:
Sail Biomedicines is an Equal Opportunity Employer. Sail does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, national origin, veteran status, or any other status protected under federal, state, or local law.